Welcome
Support Centre
06 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A comparative pharmacokinetic study: 5 Fluorouracil (5FU) provided as patient specific individual doses and as standard doses according to a "dose banding" principle
ISRCTN ISRCTN46112469
ClinicalTrials.gov identifier
Public title A comparative pharmacokinetic study: 5 Fluorouracil (5FU) provided as patient specific individual doses and as standard doses according to a "dose banding" principle
Scientific title
Acronym N/A
Serial number at source N0436118084
Study hypothesis The main aim of the project is to evaluate the concept of dose-binding chemotherapy drugs as a means of improving pharmacy efficiency and reducing patients waiting times. This study aims to compare the plasma profiles of the drug 5FU in breast cancer patients receiving dose-banded and the usual, individually prepared, doses as part of their normal FEC chemotherapy regimen.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Cancer: Breast
Participants - inclusion criteria All study participants will be women with breast cancer who are receiving adjuvant therapy.
Participants - exclusion criteria Patients on reduced doses of FEC chemotherapy, with known liver metastases, who have received chemotherapy for previous malignancies.
Anticipated start date 01/03/2002
Anticipated end date 01/03/2007
Status of trial Completed
Patient information material
Target number of participants 26
Interventions Randomised controlled trial
Primary outcome measure(s) The comparative plasma concentration profiles (Cmax, AUC) in patients receiving dose-banded and individually prepared doses of 5 Fluorouracil.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Leeds Teaching Hospitals NHS Trust
NHS R&D Support Funding
Trial website
Publications
Contact name Ms  V A  Walker
  Address Department of Medical Oncology
Level 4
Gledhow Wing
St James's University Hospital
  City/town Leeds
  Zip/Postcode LS9 7TF
  Country United Kingdom
  Tel +44 (0)113 243 3144
  Fax +44 (0)113 242 6496
  Email r&d@leedsth.nhs.uk
Sponsor Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
  Address The Department of Health, Richmond House, 79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2005
Last edited 14/12/2006
Date ISRCTN assigned 30/09/2005
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central